Biomarker Research

Papers
(The TQCC of Biomarker Research is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Metabolic reprogramming in macrophage responses261
Biomarkers for cancer-associated fibroblasts167
miR-21: a non‐specific biomarker of all maladies144
Recent advances in systemic therapy for hepatocellular carcinoma116
The landscape of bispecific T cell engager in cancer treatment114
Targeting ferroptosis in breast cancer104
CAR-NK cells for cancer immunotherapy: from bench to bedside94
A comprehensive comparison between camelid nanobodies and single chain variable fragments93
Biological roles of RNA m5C modification and its implications in Cancer immunotherapy87
Epidemiological trends of women’s cancers from 1990 to 2019 at the global, regional, and national levels: a population-based study78
Next frontier in tumor immunotherapy: macrophage-mediated immune evasion74
Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy73
Imaging biomarkers for evaluating tumor response: RECIST and beyond69
Nanobody-based CAR-T cells for cancer immunotherapy66
Blood biomarkers for mild traumatic brain injury: a selective review of unresolved issues65
Detection of circulating tumor cells: opportunities and challenges64
Immune cells-derived exosomes function as a double-edged sword: role in disease progression and their therapeutic applications62
Immunotherapy in endometrial cancer: rationale, practice and perspectives62
Alternative Polyadenylation: a new frontier in post transcriptional regulation60
The role of ferroptosis in lung cancer57
Anti-Mesothelin CAR T cell therapy for malignant mesothelioma57
Single-cell map of diverse immune phenotypes in the acute myeloid leukemia microenvironment53
Cancer-associated adipocytes as immunomodulators in cancer53
Structures and biological functions of zinc finger proteins and their roles in hepatocellular carcinoma52
The role of biomarkers in personalized immunotherapy51
Targeting interleukin-1β and inflammation in lung cancer50
Prolonged elevation of serum neurofilament light after concussion in male Australian football players49
Landscape of Myeloid-derived Suppressor Cell in Tumor Immunotherapy49
Temporal trend of gastric cancer burden along with its risk factors in China from 1990 to 2019, and projections until 2030: comparison with Japan, South Korea, and Mongolia48
p63 expression in human tumors and normal tissues: a tissue microarray study on 10,200 tumors47
Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis46
The role of phosphatidylserine on the membrane in immunity and blood coagulation46
Risk factors for immune-related adverse events: what have we learned and what lies ahead?44
Targeting CD47/SIRPα as a therapeutic strategy, where we are and where we are headed42
The landscape overview of CD47-based immunotherapy for hematological malignancies41
TOX as a potential target for immunotherapy in lymphocytic malignancies39
EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives38
Intratumor microbiome in cancer progression: current developments, challenges and future trends38
Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives38
Metastasis-associated fibroblasts: an emerging target for metastatic cancer37
Current views on the genetic landscape and management of variant acute promyelocytic leukemia36
Targeting neoantigens for cancer immunotherapy36
Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment36
Clinical translation of patient-derived tumour organoids- bottlenecks and strategies36
Dysregulated bile acid receptor-mediated signaling and IL-17A induction are implicated in diet-associated hepatic health and cognitive function36
E-Cadherin expression in human tumors: a tissue microarray study on 10,851 tumors33
Current challenges and best practices for cell-free long RNA biomarker discovery32
The Wnt signaling pathway in tumorigenesis, pharmacological targets, and drug development for cancer therapy31
The key to immunotherapy: how to choose better therapeutic biomarkers for patients with non-small cell lung cancer31
Roles and mechanisms of tumour-infiltrating B cells in human cancer: a new force in immunotherapy30
N6-methyladenine modification in noncoding RNAs and its function in cancer30
Advances of cancer-associated fibroblasts in liver cancer29
Dysfunction and ceRNA network of the tumor suppressor miR-637 in cancer development and prognosis29
Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer29
Detection and clinical significance of circulating tumor cells in colorectal cancer28
Advances in molecular biomarkers research and clinical application progress for gastric cancer immunotherapy28
Strategies to enhance CAR-T persistence28
The emerging role of RNA N6-methyladenosine methylation in breast cancer27
Novel insights into the m6A-RNA methyltransferase METTL3 in cancer27
Recent updates on Sintilimab in solid tumor immunotherapy27
Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma26
MicroRNAs as the critical regulators of cell migration and invasion in thyroid cancer26
LncRNA APCDD1L-AS1 induces icotinib resistance by inhibition of EGFR autophagic degradation via the miR-1322/miR-1972/miR-324-3p-SIRT5 axis in lung adenocarcinoma26
Functions and mechanisms of lncRNA MALAT1 in cancer chemotherapy resistance26
Advances of mRNA vaccine in tumor: a maze of opportunities and challenges25
Consolidative allogeneic hematopoietic stem cell transplantation after chimeric antigen receptor T-cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia: who? When? Why?24
CAR-T cell potency: from structural elements to vector backbone components24
Advances in the DNA methylation hydroxylase TET124
Cancer metabolites: promising biomarkers for cancer liquid biopsy24
Current and emerging therapies for primary central nervous system lymphoma24
Nucleases as molecular targets for cancer diagnosis24
The significant role of redox system in myeloid leukemia: from pathogenesis to therapeutic applications24
Extrachromosomal circular DNA (eccDNA): an emerging star in cancer24
Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma23
The intriguing roles of Siglec family members in the tumor microenvironment23
HMGA1 augments palbociclib efficacy via PI3K/mTOR signaling in intrahepatic cholangiocarcinoma23
The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies22
Haploidentical CD7 CAR T-cells induced remission in a patient with TP53 mutated relapsed and refractory early T-cell precursor lymphoblastic leukemia/lymphoma22
Longitudinal CITE-Seq profiling of chronic lymphocytic leukemia during ibrutinib treatment: evolution of leukemic and immune cells at relapse22
A phase 1 study of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor in Chinese patients with advanced breast cancer21
MiR-124-3p impedes the metastasis of non-small cell lung cancer via extracellular exosome transport and intracellular PI3K/AKT signaling21
Oncofetal protein IGF2BPs in human cancer: functions, mechanisms and therapeutic potential21
The CAR macrophage cells, a novel generation of chimeric antigen-based approach against solid tumors20
MEK inhibitors - novel targeted therapies of neurofibromatosis associated benign and malignant lesions19
Inhibition of BCL11B induces downregulation of PTK7 and results in growth retardation and apoptosis in T-cell acute lymphoblastic leukemia19
Sintilimab for the treatment of non-small cell lung cancer18
Targeting serine-glycine-one-carbon metabolism as a vulnerability in cancers18
An analysis of the role of HnRNP C dysregulation in cancers18
Novel strategies for immuno-oncology breakthroughs with cell therapy18
Imaging biomarkers for clinical applications in neuro-oncology: current status and future perspectives18
Integration of tumor inflammation, cell proliferation, and traditional biomarkers improves prediction of immunotherapy resistance and response18
Research and application of single-cell sequencing in tumor heterogeneity and drug resistance of circulating tumor cells18
The role of pyroptosis in modulating the tumor immune microenvironment18
Effect of regulatory cell death on the occurrence and development of head and neck squamous cell carcinoma18
Small biomarkers with massive impacts: PI3K/AKT/mTOR signalling and microRNA crosstalk regulate nasopharyngeal carcinoma17
Cervical cancer heterogeneity: a constant battle against viruses and drugs17
Multifaced roles of PLAC8 in cancer17
The biology of YAP in programmed cell death17
The REASON score: an epigenetic and clinicopathologic score to predict risk of poor survival in patients with early stage oral squamous cell carcinoma17
Galectins and galectin-mediated autophagy regulation: new insights into targeted cancer therapy16
FAM83A is a potential biomarker for breast cancer initiation16
Molecular mechanisms and clinical applications of exosomes in prostate cancer16
Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma16
Extracellular vesicle-based liquid biopsy biomarkers and their application in precision immuno-oncology16
The application of Aptamer in biomarker discovery16
New cell sources for CAR-based immunotherapy16
The function and clinical implication of YTHDF1 in the human system development and cancer15
KMT2A/C mutations function as a potential predictive biomarker for immunotherapy in solid tumors15
Minimal residual disease in multiple myeloma: current status14
Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives14
Oncolytic viruses for triple negative breast cancer and beyond14
Review immune response of targeting CD39 in cancer14
Donor T cells for CAR T cell therapy14
Direct and indirect effects of IFN-α2b in malignancy treatment: not only an archer but also an arrow14
Emerging treatment modalities for systemic therapy in hepatocellular carcinoma14
0.052149057388306